|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:bfsLayer
|
4
|
|
gptkbp:bfsParent
|
gptkb:Nexium
|
|
gptkbp:activities
|
gptkb:railway_station
|
|
gptkbp:appointed_by
|
oral tablet
intravenous injection
|
|
gptkbp:approves
|
gptkb:2001
gptkb:FDA
|
|
gptkbp:brand
|
gptkb:Nexium_24_HR
gptkb:Nexium_IV
gptkb:Nexium
|
|
gptkbp:category
|
Category C
|
|
gptkbp:class
|
proton pump inhibitors
|
|
gptkbp:clinical_trial
|
64% to 89%
|
|
gptkbp:contraindication
|
severe liver disease
hypersensitivity to esomeprazole
|
|
gptkbp:dosage_form
|
20 mg to 40 mg daily
|
|
gptkbp:duration
|
4 to 8 weeks for GERD
up to 6 months for Zollinger-Ellison syndrome
|
|
gptkbp:formulation
|
oral suspension
delayed-release capsule
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
esomeprazole
|
|
gptkbp:ingredients
|
C17 H19 N3 O3 S
|
|
gptkbp:interacts_with
|
gptkb:methotrexate
gptkb:clopidogrel
gptkb:digoxin
gptkb:warfarin
|
|
gptkbp:invention
|
gptkb:2014
|
|
gptkbp:is_available_on
|
generic version
|
|
gptkbp:is_used_for
|
treating gastroesophageal reflux disease (GERD)
treating peptic ulcers
treating Zollinger-Ellison syndrome
|
|
gptkbp:lifespan
|
about 1.3 hours
|
|
gptkbp:marketed_as
|
gptkb:temple
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:research
|
ongoing studies for efficacy in other conditions
|
|
gptkbp:side_effect
|
headache
nausea
abdominal pain
diarrhea
flatulence
|
|
gptkbp:storage
|
room temperature
|
|
gptkbp:type_of
|
161796-78-7
|